Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
Seventh Indication Secured For Blockbuster
Executive Summary
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
You may also be interested in...
Novartis Keen On Cardio Deals But Obesity Ship Has Sailed
The Swiss major is sticking to a bolt-on M&A strategy in its key areas and a deal in the obesity space is highly unlikely unless it involves "leapfrogging" what is already available.
AbbVie Ups Efforts In HS And Advances Lutikizumab Into Phase III
There are a raft of investigational products looking to move into the rapidly growing hidradenitis suppurativa market and AbbVie is hoping to grab a decent share with two assets, the anti-interleukin-1 alpha and beta monoclonal antibody lutikizumab and its anti-inflammatory blockbuster Rinvoq.
The Runners And Riders In Hidradenitis Suppurativa
Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market.